OGT and ovarian carcinoma: This destructive act by OGT against Nrf2 may be blocked (Point 11) by the action of miR-181d—an inhibitor of OGT [22] found to target the 3’UTR of OGT mRNA to prevent OGT expression in ovarian cancer, elevating Nrf2 activation and providing cisplatin resistance.